Table 6.
Demographic and anamnestic determinants of COVID-19 vaccine booster uptake among polish healthcare professionals and students responding to COVID-19 VBH survey, December 2021–January 2022 (n = 443).
| Variable | Outcome |
Did not receive COVID-19 BD (n = 136) |
Received COVID-19 BD (n = 307) |
Sig. |
|---|---|---|---|---|
| Gender | Female* | 100 (29.6%) | 238 (70.4%) | Reference |
| Male | 36 (35.6%) | 65 (64.4%) | 0.249 | |
| Diverse-gender | 0 (0%) | 4 (100%) | 0.984 | |
| Pregnancy* | Yes | 4 (57.1%) | 3 (24.9%) | 0.202 |
| No | 96 (29%) | 235 (71%) | ||
| Age group | >30 years-old | 88 (33.2%) | 177 (66.8%) | 0.174 |
| ≤ 30 years-old | 48 (27.1%) | 129 (72.9%) | ||
| Prior COVID-19 infection | Yes† | 59 (41.8%) | 82 (58.2%) | <0.001 |
| No | 77 (25.5%) | 225 (74.5%) | ||
| Onset† | Before 1st dose | 40 (38.8%) | 63 (61.2%) | Reference |
| Between 1/2 doses | 4 (66.7%) | 2 (33.3%) | 0.197 | |
| After 2nd dose | 15 (46.9%) | 17 (53.1%) | 0.420 | |
| Severity† | Asymptomatic | 3 (75%) | 1 (25%) | Reference |
| Mild | 38 (40.9%) | 55 (59.1%) | 0.211 | |
| Moderate | 17 (41.5%) | 24 (58.5%) | 0.228 | |
| Severe | 1 (33.3%) | 2 (66.7%) | 0.287 | |
| Vaccine type | Pfizer-BioNTech | 65 (20%) | 260 (80%) | <0.001 |
| Moderna | 4 (20%) | 16 (80%) | 0.529 | |
| AstraZeneca-Oxford | 23 (42.6%) | 31 (57.4%) | 0.003 | |
| Janssen | 16 (100%) | 0 (0%) | <0.001 | |
| Hospital admission | Yes | 7 (50%) | 7 (50%) | 0.058 |
| No | 101 (25.2%) | 300 (74.8%) | ||
| Medical care | Yes | 8 (44.4%) | 10 (55.6%) | 0.095 |
| No | 100 (25.2%) | 297 (74.8%) |
Logistic regression, Chi-squared test (χ2) and Fisher's exact test had been used with a significance level (Sig.) <0.05.
*
Refers to female participants.
†
Refers to the previously infected participants.
‡
Refers to the previously vaccinated participants.
Bold values - statistically significant with p <0.05.